Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29, 2024, the company granted equity awards to one new employee, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to such new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics是一家臨床階段的公司，正在開發一類新型心血管疾病基因藥物，今天宣佈，於2024年11月29日，公司根據納斯達克規則5635(c)(4)向一名新員工授予股權獎勵，作爲該新員工進入公司就職的重要誘因，依據公司的2024年誘因股票激勵計劃。
The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such employee's continued service with the company on each such vesting date.
該員工獲得了共計5,330個受限制的股票單位（RSUs）。這些RSUs將在2025年1月1日的頭四個週年紀念日以相等的年度分期解禁，前提是該員工在每個解禁日期繼續爲公司提供服務。
About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic management to single-course gene editing medicines. The company's lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for refractory hypercholesterolemia, where patients still have high LDL-C despite treatment with maximally tolerated standard of care therapies, and homozygous familial hypercholesterolemia (HoFH). For more information, please visit .
關於Verve Therapeutics
Verve Therapeutics，Inc.(納斯達克代碼：VERV)是一家臨床階段的遺傳藥品公司，開創了一種新的心血管疾病護理方式，可能將治療從慢性管理轉變爲單次基因編輯藥品。公司的主要項目VERVE-101、VERVE-102和VERVE-201針對已被廣泛驗證爲低密度脂蛋白膽固醇（LDL-C）降低的靶點基因，這是動脈粥樣硬化性心血管疾病（ASCVD）的根本原因。VERVE-101和VERVE-102旨在永久關閉肝臟中的PCSK9基因，並首先開發用於雜合子家族性高膽固醇血癥（HeFH），最終用於治療繼續受高LDL-C水平影響的已確診ASCVD患者。VERVE-201旨在永久關閉一種受體基因，該基因的降解被認爲是促進冠狀動脈血管單位深度和體積增加的關鍵步驟，因此是一種可能的靶切點，因爲它可能降低心血管病發作的風險。
Verve Therapeutics，Inc.（納斯達克：VERV）是一家臨床階段的公司，正在開發一類新型心血管疾病基因藥物，有潛力將治療從慢性管理轉變爲單療程基因編輯藥物。該公司的主要項目-VERVE-101、VERVE-102和VERVE-201-瞄準已被廣泛驗證爲降低低密度脂蛋白膽固醇（LDL-C）的靶點基因，LDL-C是動脈粥樣硬化心血管疾病（ASCVD）的根本原因。VERVE-101和VERVE-102旨在永久關閉肝臟中的PCSK9基因，最初用於雜合子家族性高膽固醇血癥（HeFH），最終用於治療已受高LDL-C水平影響的已確診ASCVD患者。VERVE-201旨在永久關閉肝臟中的ANGPTL3基因，最初用於難治性高膽固醇血癥，即患者儘管接受了最大可耐受的標準護理療法治療，仍然具有高LDL-C水平，以及純合子家族性高膽固醇血癥（HoFH）。欲了解更多信息，請訪問。
Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com
投資者聯繫人
詹·羅賓遜
Verve Therapeutics，Inc。
jrobinson@vervetx.com
Media Contact
Ashlea Kosikowski
1AB
ashlea@1abmedia.com
媒體聯繫
阿什莉·科西科夫斯基
1AB
ashlea@1abmedia.com
譯文內容由第三人軟體翻譯。
